Clinical trials: Neuroendocrine (NE) Tumors
Healthy (Controls), Healthy Volunteers
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring.
- Conditions
- Healthy (Controls), Healthy Volunteers, Neuroendocrine (NE) Tumors
- Trial name
- NCT07284589
- Testing
- 68Ga-Dotatate
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz
Neuroendocrine (NE) Tumors, Liver Metastasis
The Role of Intraoperative Hepatic Ultrasonography in Gastrointestinal or Pancreatic Neuroendocrine Tumor
Background: Liver metastases are common in patients with neuroendocrine neoplasms, but often underestimated by preoperative imaging.
- Trial name
- ECHO-NET (NCT06779708)
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Istituto Clinico Humanitas
Neuroendocrine (NE) Tumors
Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors
Prior clinical trials have demonstrated promising efficacy and manageable safety of surufatinib in neuroendocrine tumors (NETs).
- Trial name
- NCT07780539
- Testing
- Surufatinib Administration
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yefeng
Neuroendocrine (NE) Tumors, Advanced NET of GI Origin
AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)
A phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours.
- Trial name
- BHARAT-3 (NCT07640737)
- Testing
- AUR103 Calcium
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Aurigene Discovery Technologies Limited
Tumor Burden, Neuroendocrine (NE) Tumors
Multicenter Study for External Validation of the TB-NET Score
This is a retrospective, observational, multicenter study aiming to externally validate the TB-NET Score in an independent cohort of patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors…
- Trial name
- TB-NET (NCT07903532)
- Where
- 11 sites in United States, Brazil and 7 more
- Volunteers
- 400 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Neuroendocrine (NE) Tumors, Metastasis
Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study
When possible, surgery to completely remove small intestinal neuroendocrine tumors (siNETs) is always recommended. However, in cases where the tumor has spread and cannot be cured completely, it is unclear whether a surgical…
- Conditions
- Neuroendocrine (NE) Tumors, Metastasis, Bowel Obstruction
- Trial name
- ENETSSurgSmInt (NCT06787014)
- Testing
- Histopathological review
- Where
- Switzerland
- Volunteers
- 3,200 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Neuroendocrine (NE) Tumors, Oral Anti-Tumor Drugs
Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education Program
In recent years, the arrival of targeted oral therapies has greatly changed cancer treatment. These therapies help patients stay independent by reducing the number of hospital visits, since the treatment is given at home.
- Conditions
- Neuroendocrine (NE) Tumors, Oral Anti-Tumor Drugs, Therapeutic Education Program
- Trial name
- ETP-NET (NCT07258810)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Solid Tumor Cancer, Castration Resistant Prostate Cancer
Imaging of Solid Tumors Using DLL3 SPECT
This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors.
- Conditions
- Solid Tumor Cancer, Castration Resistant Prostate Cancer, Castration Resistant Prostate Cancer (CRPC), Neuroendocrine (NE) Tumors
- Trial name
- NCT07052760
- Testing
- 111In-ABD147, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)
- Sponsor
- Thomas Hope
Small Cell Lung Cancer (SCLC), Neuroendocrine (NE) Tumors
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
There are two parts to this trial. The first study will evaluate increasing doses of Re188 P2045 in patients with advanced small cell lung cancer that has recurred after initial therapy or in patients with other advanced…
- Conditions
- Small Cell Lung Cancer (SCLC), Neuroendocrine (NE) Tumors, Large Cell Neuroendocrine (NE) Tumors
- Trial name
- NCT02030184
- Testing
- Rhenium Re 188-P2045
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Neuroendocrine (NE) Tumors
Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor
Advanced neuroendocrine tumors (NETs) are rare cancers, characterized by prolonged survival (median>5 years). If five medical options are now approved and 4 others are only recommended, the best sequence is still unknown.
- Trial name
- TOLERATE (NCT07471425)
- Testing
- quality of life questionnaire, treatment side effect follow up
- Where
- 14 sites in France
- Volunteers
- 1,100 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Neuroendocrine (NE) Tumors
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]octreotate (177Lu-Dotatate) is an effective and safe treatment for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NET).
- Trial name
- NCT07012330
- Testing
- Capecitabine (Xeloda), 177Lu-DOTATATE
- Volunteers
- 111 people
- Sponsor
- Erasmus Medical Center
Small Bowel Neoplasia, Neuroendocrine (NE) Tumors
Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel
The neuroendocrine neoplasms of the small intestine (Si-NENs) is a relatively rare malignancy. Surgical resection is the only curative treatment for the early-stage.
- Trial name
- NCT06773624
- Testing
- PET/CT-enterography with 68Ga-DOTATOC
- Where
- Italy
- Volunteers
- 18 people
- Sponsor
- European Institute of Oncology
Neuroendocrine Tumors
Entinostat Neuroendocrine (NE) Tumor
This is an open-label, single arm, multi-center Phase II trial of entinostat given as a 5 mg oral dose every week (days 1, 8, 15, and 22 of a 4-week cycle) in patients with relapsed or refractory abdominal neuroendocrine (NE)…
- Trial name
- NCT03211988
- Testing
- Entinostat
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Antonio Fojo
Neuroendocrine (NE) Tumors, Neuroendocrine Tumor GEP Grade 1-3
Life Following Excision of Neuroendocrine Tumors
Neuroendocrine tumors (NETs), often seen as "chronic cancer" present a survival paradox with relatively prolonged patient survival despite active disease.
- Trial name
- LIFENETS (NCT06981455)
- Where
- Canada
- Volunteers
- 246 people
- Sponsor
- Sunnybrook Health Sciences Centre
Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic…
- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood
- Trial name
- STRATUS (NCT06717243)
- Testing
- Carboplatin/Cisplatin -Etoposide - Atezolizumab
- Where
- 2 sites in United States, Greece
- Volunteers
- 111 people
- Sponsor
- Oncology Center of Biochemical Education And Research
Advanced Prostate Cancer, Metastatic Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low…
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT06062745
- Testing
- 18F-fluciclovine, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Neuroendocrine (NE) Tumors, Endocrine Cancer
Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms
It has been showed that alkylating chemotherapy, particularly the widely used agent temozolomide, may cause high tumor mutational burden (TMB) in certain tumors by causing inactivating mutations in the DNA mismatch repair (MMR)…
- Trial name
- PROGRESS-TMZ (NCT07121998)
- Testing
- Core needle biopsy, Phlebotomy
- Where
- Sweden
- Volunteers
- 94 people
- Sponsor
- Uppsala University
Heathy Volunteer, Parkinsonian Syndromes
Ultralow Dose PET Imaging of 18F-FDOPA
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring.
- Conditions
- Heathy Volunteer, Parkinsonian Syndromes, Neuroendocrine (NE) Tumors, Gliomas
- Trial name
- NCT07542158
- Testing
- 18F-FDOPA
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Akiva Mintz